

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Approval for Drug Registration of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

29 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval for Drug Registration of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug registration application for Shaoyao Gancao Tang Granules (芍藥甘草湯顆粒, the “**Drug**”) of Hebei Wanbang Folon Pharmaceutical Co., Ltd.* (河北萬邦復臨藥業有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “**Company**”), has been approved by the National Medical Products Administration.

II. Registration Information of the Drug

Generic Name: Shaoyao Gancao Tang Granules

Dosage Form: Granules

Strength: Each sachet equivalent to 27.60 g of decoction pieces

Registered Category: Traditional Chinese Medicine, Class 3.1

Marketing Authorization Holder/Manufacturer : Hebei Wanbang Folon Pharmaceutical Co., Ltd.* (河北萬邦復臨藥業有限公司)

Drug Approval Number: Guo Yao Zhun Zi C20260017

III. Research and Development of the Drug and Marketing Situation of Similar Drugs

The formulation of the Drug originates from Cold Pathogenic Diseases (《傷寒論》) written by Zhang Zhongjing (張仲景) from the Han Dynasty, and has been listed in the "Catalogue of Ancient Classic Famous Recipes (First Batch)" (《古代經典名方目錄(第一批)》) by the National Administration of Traditional Chinese Medicine. It is used for various spasm and pain conditions caused by insufficiency of yin and blood and malnourishment of the sinews and vessels, manifested as spasms of the legs and feet, and abdominal pain. As of May 2026, the Group (i.e., the Company and its subsidiaries/units, the same hereinafter) has invested approximately RMB5.91 million (unaudited) in total in the research and development of the Drug at current stage.

As of the date of this Announcement (i.e. 29 June 2026), four additional types of Shaoyao Gancao Tang Granules have been approved for marketing in China (excluding Hong Kong, Macao, and Taiwan regions), in January 2025, June 2025, June 2025, and April 2026, respectively. Their sales in China for 2025 cannot yet be retrieved from IQVIA CHPA¹.

IV. Impact on the Listed Company and Risk Warning

This approval for marketing of the Drug will further enrich the product line of the Group.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

¹ Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data cover the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.

** For identification purposes only*